Anup Y. Parikh
A5028414393- CAR-T cell therapy research
- Virus-based gene therapy research
- Cancer Research and Treatments
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- CRISPR and Genetic Engineering
- DNA Repair Mechanisms
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Renal and related cancers
- Cancer therapeutics and mechanisms
- Immune Cell Function and Interaction
National Cancer Institute
2020-2023
Center for Cancer Research
2022-2023
National Institutes of Health
2022-2023
BACKGROUND. Therapeutic vaccinations against cancer have mainly targeted differentiation antigens, cancer-testis and overexpressed antigens thus far resulted in little clinical benefit. Studies conducted by multiple groups demonstrated that T cells recognizing neoantigens are present most cancers offer a specific highly immunogenic target for personalized vaccination.
The accurate identification of antitumor T cell receptors (TCRs) represents a major challenge for the engineering cell-based cancer immunotherapies. By mapping 55 neoantigen-specific TCR clonotypes (NeoTCRs) from 10 metastatic human tumors to their single-cell transcriptomes, we identified signatures CD8
PURPOSE Metastatic breast cancer (mBrCa) is most often an incurable disease with only modest responses to available immunotherapies. This study investigates the immunogenicity of somatic mutations in and explores therapeutic efficacy a pilot trial mutation-reactive tumor-infiltrating lymphocytes (TILs) patients metastatic disease. PATIENTS AND METHODS Forty-two mBrCa refractory previous lines treatment underwent surgical resection lesion(s), isolation TIL cultures, identification exomic...
Abstract Colorectal cancers (CRCs) are prevalent worldwide, yet current treatments remain inadequate. Using chemical genetic screens, we identify that co-inhibition of topoisomerase I (TOP1) and NEDD8 is synergistically cytotoxic in human CRC cells. Combination the TOP1 inhibitor irinotecan or its bioactive metabolite SN38 with NEDD8-activating enzyme pevonedistat exhibits synergy patient-derived organoids xenografts. Mechanistically, show blocks ubiquitin/proteasome-dependent repair...
Adoptive cell transfer of tumor-infiltrating lymphocytes (TIL) can mediate durable complete responses in some patients with common epithelial cancers but does so infrequently. A better understanding T-cell to neoantigens and tumor-related immune evasion mechanisms requires having the autologous tumor as a reagent. We investigated ability patient-derived organoids (PDTO) fulfill this need evaluated their utility tool for selecting T-cells adoptive therapy. PDTO established from metastases...
<h3>Background</h3> Adoptive cellular transfer (ACT) of autologous tumor-infiltrating lymphocytes (TIL) is capable inducing durable clinical responses in patients with advanced solid malignancies,<sup>1</sup> however response rates are low. Limitations personalized cancer modeling have been obstacles to understanding tumor-specific mechanisms immune evasion. Patient-derived tumor organoids (PDTO) can be efficiently grown from common tumors and show genetic fidelity whole exomic sequencing...
<div>Abstract<p>Adoptive cellular therapy (ACT) targeting neoantigens can achieve durable clinical responses in patients with cancer. Most arise from patient-specific mutations, requiring highly individualized treatments. To broaden the applicability of ACT neoantigens, we focused on <i>TP53</i> mutations commonly shared across different cancer types. We performed whole-exome sequencing 163 metastatic solid cancers, identified 78 who had missense and through...
Supplementary Figure from Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors
Supplementary Data from Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors
Supplementary Figure from Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors
Supplementary Data from Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors
<div>Abstract<p>Adoptive cellular therapy (ACT) targeting neoantigens can achieve durable clinical responses in patients with cancer. Most arise from patient-specific mutations, requiring highly individualized treatments. To broaden the applicability of ACT neoantigens, we focused on <i>TP53</i> mutations commonly shared across different cancer types. We performed whole-exome sequencing 163 metastatic solid cancers, identified 78 who had missense and through...